Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Advanced Energy Industries, Inc.

11% sales growth and 14.52% return on equity

Advanced Energy Industries, Inc. designs, manufactures, sells, and supports precision power conversion, measurement, and control solutions worldwide.

Advanced Energy Industries, Inc.’s sales growth this year is expected to be 78.7% and 5.9% for next year.

Year-on-year quarterly revenue growth grew by 122.4%, now sitting on 1.38B for the twelve trailing months.

Advanced Energy Industries, Inc.’s sales growth for the next quarter is 11%. The company’s growth estimates for the current quarter and the next is 54% and 26.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.52%.

Volatility

Advanced Energy Industries, Inc.’s last day, last week, and last month’s average volatility was a negative 0.22%, a negative 0.05%, and a negative 0.14%, respectively.

Advanced Energy Industries, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.18%, 2.69%, and 3.19%, respectively.

Advanced Energy Industries, Inc.’s Stock Yearly Top and Bottom Value

Advanced Energy Industries, Inc.’s stock is valued at $96.97 at 06:29 EST, below its 52-week high of $104.43 and way higher than its 52-week low of $33.38.

Advanced Energy Industries, Inc.’s Moving Average

Advanced Energy Industries, Inc.’s value is above its 50-day moving average of $95.90 and way above its 200-day moving average of $76.35.

2. Green Dot Corporation

5.3% sales growth and 5.05% return on equity

Green Dot Corporation operates as a financial technology and bank holding company in the United States.

Green Dot Corporation’s sales growth this year is anticipated to be 12.5% and 3.7% for next year.

Year-on-year quarterly revenue growth grew by 21.1%, now sitting on 1.22B for the twelve trailing months.

Green Dot Corporation’s sales growth for the next quarter is 5.3%. The company’s growth estimates for the current quarter and the next is 28.6% and negative -3.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.05%.

Volatility

Green Dot Corporation’s last day, last week, and last month’s average volatility was a negative 2.86%, a negative 1.46%, and a negative 0.26%, respectively.

Green Dot Corporation’s last day, last week, and last month’s high and low average amplitude percentage was 5.51%, 4.01%, and 4.37%, respectively.

Green Dot Corporation’s Stock Yearly Top and Bottom Value

Green Dot Corporation’s stock is valued at $53.19 at 06:29 EST, way below its 52-week high of $64.97 and way higher than its 52-week low of $14.20.

Green Dot Corporation’s Moving Average

Green Dot Corporation’s worth is under its 50-day moving average of $55.45 and higher than its 200-day moving average of $52.93.

3. ACM Research, Inc.

69.9% sales growth and 10.8% return on equity

ACM Research, Inc., together with its subsidiaries, develops, manufactures, and sells single-wafer wet cleaning equipment for enhancing the manufacturing process and yield for integrated chips worldwide.

ACM Research, Inc.’s sales growth this year is anticipated to be 40.4% and 36.4% for next year.

Year-on-year quarterly revenue growth grew by 42.6%, now sitting on 135.67M for the twelve trailing months.

ACM Research, Inc.’s sales growth for the next quarter is 69.9%. The company’s growth estimates for the present quarter and the next is 4.3% and 145.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.8%.

Volatility

ACM Research, Inc.’s last day, last week, and last month’s average volatility was a positive 0.56%, a positive 3.36%, and a negative 0.09%, respectively.

ACM Research, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 7.61%, 9.04%, and 6.41%, respectively.

ACM Research, Inc.’s Stock Yearly Top and Bottom Value

ACM Research, Inc.’s stock is valued at $81.25 at 06:29 EST, way under its 52-week high of $113.87 and way higher than its 52-week low of $15.95.

ACM Research, Inc.’s Moving Average

ACM Research, Inc.’s worth is above its 50-day moving average of $76.36 and above its 200-day moving average of $79.54.

4. Merchants Bancorp

35.5% sales growth and 21.75% return on equity

Merchants Bancorp operates as the diversified bank holding company in the United States.

Merchants Bancorp’s sales growth this year is expected to be 95.1% and a negative 4.5% for next year.

Year-on-year quarterly revenue growth grew by 138.9%, now sitting on 290.26M for the twelve trailing months.

Merchants Bancorp’s sales growth for the next quarter is 35.5%. The company’s growth estimates for the ongoing quarter and the next is 62% and 58.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.75%.

Volatility

Merchants Bancorp’s last day, last week, and last month’s average volatility was 0.72%, 0.00%, and 0.21%, respectively.

Merchants Bancorp’s last day, last week, and last month’s high and low average amplitude percentage was 3.45%, 4.18%, and 4.14%, respectively.

Merchants Bancorp’s Stock Yearly Top and Bottom Value

Merchants Bancorp’s stock is valued at $27.83 at 06:29 EST, below its 52-week high of $30.84 and way higher than its 52-week low of $12.37.

Merchants Bancorp’s Moving Average

Merchants Bancorp’s worth is higher than its 50-day moving average of $27.66 and way higher than its 200-day moving average of $21.69.

5. Astrazeneca PLC

7.3% sales growth and 17.71% return on equity

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.

Astrazeneca PLC’s sales growth this year is anticipated to be 7.6% and 15.2% for next year.

Year-on-year quarterly revenue growth grew by 2.7%, now sitting on 25.87B for the twelve trailing months.

Astrazeneca PLC’s sales growth for the next quarter is 7.3%. The company’s growth estimates for the present quarter and the next is 42.2% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.71%.

Volatility

Astrazeneca PLC’s last day, last week, and last month’s average volatility was a positive 1.77%, a negative 0.34%, and a negative 0.32%, respectively.

Astrazeneca PLC’s last day, last week, and last month’s high and low average amplitude percentage was 2.32%, 1.61%, and 1.75%, respectively.

Astrazeneca PLC’s Stock Yearly Top and Bottom Value

Astrazeneca PLC’s stock is valued at $49.38 at 06:29 EST, way below its 52-week high of $64.94 and way higher than its 52-week low of $36.15.

Astrazeneca PLC’s Moving Average

Astrazeneca PLC’s value is under its 50-day moving average of $53.22 and below its 200-day moving average of $54.27.

LEAVE A REPLY

Please enter your comment!
Please enter your name here